Cleveland Review of Rheumatic Diseases 2026

Continuing Medical Education

May 1-2, 2026

Presented by University Hospitals Cleveland Medical Center

Sponsored by Case Western Reserve University School of Medicine

Tinkham Veale University Center | CWRU Campus
11038 Bellflower Rd
Cleveland, OH 44106

Who Should Attend

This course content is intended for rheumatology specialists, internists, and family practice physicians. Nurses and other allied health professionals are also welcome to attend and will benefit from the course agenda.

PROGRAM AGENDA

Day 1 | May 1, 2026

7:00 - 8:00 a.m. | Registration, Exhibits and Continental Breakfast

8:00 – 8:05 a.m.
Welcome & Introduction
Marina Magrey, MD* &  Vicky Nahra, MD*

SESSION I |  Novel Treatments in Rheumatic Diseases

Moderators: Donald Anthony, MD* and Lenche Kostadinova, MD

8:05 – 8:40 a.m.
Novel Treatments for Scleroderma Including Car-T Cells| Keynote
Dinesh Khanna, MBBS, Msc
Professor of Internal Medicine
University of Michigan Medical School

8:40 – 9:15 a.m.
GLP1s and What Rheumatologists Should Know About?
Philip J. Mease, MD
Director of Rheumatology Research
Swedish Medical Center/Providence-St. Joseph Health
Clinical Professor, University of Washington School of Medicine, Seattle, WA

9:15 – 9:50 a.m.
Rheumatoid Arthritis Treatment Updates
Jack Cush, MD
Executive Editor of RheumNow.com

9:50 – 10:10 a.m. | Questions and Answer Session

10:10 – 10:30 a.m. | Break

Moderators: Van Warren, MD and Maria Antonelli, MD

10:30 – 11:05 a.m.
CTD-ILD New Treatment
John T. Giles, MD, MPH
Director, Inflammatory Arthritis Clinical Center
Cedars-Sinai Medical Center

11:05 – 11:40 a.m.
Emerging Therapies in Lupus
George Tsokos, MD
Chief of Rheumatology and Clinical Immunology, Beth Israel Deaconess Medical Center
Professor of Medicine, Harvard Medical School 

11:40 a.m. – 12:00 p.m. | Question & Answer Session

12:00 – 1:00 p.m. Lunch & Learn 

Product Theaters:

Room 222 | Session 1
Room 111 | Session 2
Room 333 | Session 3

SESSION II | Connective Tissue Diseases

Moderators: Rula Hajj-Ali, MD* and Elisabeth Roter, MD*

1:00 – 1:35 p.m.
Update on the Treatment of ANCA-Associated Vasculitis
Carol Langford, MD, MHS
Director, Center for Vasculitis Care and Research
Cleveland Clinic

1:35 – 2:10 p.m.
Difficult to Treat Spondyloarthritis
Marina Magrey, MD*

2:10 – 2:45 p.m.
Derm Manifestations of Rheumatic Diseases
Bethany Rohr, MD*

2:45 – 3:00 p.m. | Questions & Answer Session

3:00 – 3:15 p.m. | Break & Exhibits

Moderators: Ogechi Moh, MD* and Krista Topalsky, MD*

3:15 – 3:50 p.m.
Osteoporosis Update
Sarah Keller, DO*

3:50 – 4:50 p.m.
Case Discussions | Rheumatology Fellows
Vicky Nahra, Ansaam Daoud, MD*, Lenche Kostadinova, MD* or/and Maya Mattar, MD*

4:50 – 5:10 p.m. | Question & Answer Session

5:10 – 5:15 p.m. | Closing Remarks

Day 2 | May 2, 2026

7:00 - 8:00 a.m. | Registration, Exhibits & Continental Breakfast

8:00 – 8:05 a.m. Welcome & Introduction
Marina Magrey, MD* and Vicky Nahra, MD*

SESSION III | Axial Diseases and Psoriatic Arthritis

Moderators: Marwa Sabha, MD* and Nora Singer, MD

8:05 – 8:40 a.m.
Psoriatic Arthritis New Treatments
M. Elaine Husni, MD, MPH
Vice Chair, Dept of Rheumatic and Immunologic Diseases
Cleveland Clinic

8:40 – 9:15 a.m.
Axial Spondylarthritis New Treatment
Dennis Poddubnyy, MD
Division of Rheumatology, Department of Medicine
Professor of Medicine
Temerty Faculty of Medicine
University of Toronto
Senior Scientist
Director of Advanced Imaging Studies for Rheumatic Diseases Program
Co-director of Gladman-Krembil Psoriatic Arthritis Program, Schroeder Arthritis Institute
Kembil Research Institute
University Health Network 

9:15 – 9:50 a.m.
Uveitis 
Shree Kurup, MD*

9:50 – 10:10 a.m. | Questions & Answer Session

10:10 – 10:30 a.m. | Break & Exhibits

SESSION IV | MSK/Ultrasound

Moderators: Lauren Mathais, MD and Lawerence Kent, MD

10:30 – 11:10 a.m.
MSK Ultrasound Overview
Haseeb Chaudhary, MD*

11:10 – 11:50 a.m.
Use of MSK Ultrasound in PsA
Sibil Ayedin, MD
Associate Scientist, Infammation and Chronic Disease
Ottawa Hospital Research Institute
Professor, Faculty of Medicine, Division of Rheumatology
University of Ottawa

11:50 – 12:30 a.m.
US Use in SS, GCA
Minna Kohler, MD
Director, Rheumatology Musculoskeletal Ultrasound Program
Massachusetts General Hospital, Harvard Medical School

12:30 a.m. – 12:35 p.m. | Closing Remarks

Registration

Tuition
Physician | $325
Cleveland Society of Rheumatology member and UH Alumni | $225
Allied Health Professional | $175
Resident/Fellow | Free Complimentary with letter from Program Director documenting residency status.
International | Complimentary
Corporate | $500

* After April 1st, prices increase $50

Online registration, full program details, accommodation information, and more can be found at https://cwru.cloud-cme.com/RHEUMATICDISEASECLE26

Learning objectives:

At the conclusion of this symposium, participants will be able to:

1. Describe the mechanisms, clinical evidence, and safety considerations of emerging therapies for scleroderma, with a focus on novel chimeric antigen receptor (CAR) T-cell therapy, including its application in refractory systemic sclerosis, patient selection, efficacy in organ and skin involvement, and current limitations and future directions.
2. Summarize recent updates in rheumatoid arthritis treatment, including biosimilars, new treatment modalities, new drug approvals, updated guidelines, and personalized medicine approaches.
3. Outline current best practices for treating connective tissue disease–associated interstitial lung disease (CTD-ILD), including antifibrotics, immunosuppressants, and emerging targeted therapies.
4. Evaluate emerging therapies in lupus and vasculitis, including new biologics, small molecules, and cell-based therapies, and their impact on disease control and patient outcomes.
5. Update knowledge in axial spondyloarthritis, including new modalities and treatments that improve long-term outcomes and quality of life.
6. Describe the utility of musculoskeletal ultrasound in rheumatology, including its role in diagnosis, disease monitoring, and guiding interventions in conditions such as Sjögren’s syndrome, psoriatic arthritis, and rheumatoid arthritis.
7. Discuss the potential utility of GLP-1 receptor agonists in autoimmune rheumatic diseases, focusing on mechanisms, metabolic and inflammatory effects, and emerging clinical data.
8. Recognize strategies for managing difficult-to-treat rheumatic diseases, emphasizing refractory cases, the integration of novel therapies, and individualized patient-centered approaches.
9. Identify and manage dermatologic and ophthalmologic manifestations of rheumatic diseases, understanding their diagnostic significance, systemic implications, and targeted treatment options.

*Denotes University Hospitals Cleveland Medical Center/CWRU School of Medicine faculty and staff.

Accreditation

MOC Credit
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 11 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

AMA Credit
Case Western Reserve University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Case Western Reserve University School of Medicine designates this live activity for a maximum of 11 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.